These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9109740)

  • 21. [Hereditary cerebellar ataxia: clinical analysis of 18 cases].
    Wang ML
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1986 Jun; 19(3):155-7. PubMed ID: 3757631
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of cerebellar ataxia with buspirone: a double-blind study.
    Trouillas P; Xie J; Adeleine P
    Lancet; 1996 Sep; 348(9029):759. PubMed ID: 8806320
    [No Abstract]   [Full Text] [Related]  

  • 23. [Theoretical basis and proposals for neuropharmacology of cerebellar ataxia].
    Trouillas P
    Rev Neurol (Paris); 1993; 149(11):637-46. PubMed ID: 7916472
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type.
    Sevush S; Guterman A; Villalon AV
    J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials.
    Nishizawa M; Onodera O; Hirakawa A; Shimizu Y; Yamada M;
    J Neurol Neurosurg Psychiatry; 2020 Mar; 91(3):254-262. PubMed ID: 31937586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock: study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se).
    Zimmermann JB; Pinder N; Bruckner T; Lehmann M; Motsch J; Brenner T; Hoppe-Tichy T; Swoboda S; Weigand MA; Hofer S
    Trials; 2017 Nov; 18(1):530. PubMed ID: 29126416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trial of oral physostigmine in amyotrophic lateral sclerosis.
    Norris FH; Tan Y; Fallat RJ; Elias L
    Clin Pharmacol Ther; 1993 Dec; 54(6):680-2. PubMed ID: 8275623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of buspirone for treatment of cerebellar ataxia. An open-label study.
    Lou JS; Goldfarb L; McShane L; Gatev P; Hallett M
    Arch Neurol; 1995 Oct; 52(10):982-8. PubMed ID: 7575226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disorderly walks.
    Grimm RJ
    Neurol Clin; 1984 Aug; 2(3):615-31. PubMed ID: 6533472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study.
    Frattali CM; Sonies BC; Chi-Fishman G; Litvan I
    Dysphagia; 1999; 14(3):165-8. PubMed ID: 10341115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physostigmine reversal of diazepam-induced hypnosis. A study in human volunteers.
    Avant GR; Speeg KV; Freemon FR; Schenker S; Berman ML
    Ann Intern Med; 1979 Jul; 91(1):53-5. PubMed ID: 380427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
    Wettstein A
    Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral physostigmine as treatment for dementia of the Alzheimer type: a long-term outpatient trial.
    Jenike MA; Albert MS; Baer L
    Alzheimer Dis Assoc Disord; 1990; 4(4):226-31. PubMed ID: 2264980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physostigmine treatment of progressive supranuclear palsy.
    Litvan I; Gomez C; Atack JR; Gillespie M; Kask AM; Mouradian MM; Chase TN
    Ann Neurol; 1989 Sep; 26(3):404-7. PubMed ID: 2802540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
    Schwartz AS; Kohlstaedt EV
    Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients.
    Ince Gunal D; Agan K; Afsar N; Borucu D; Us O
    J Clin Pharm Ther; 2008 Apr; 33(2):175-8. PubMed ID: 18315783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A preliminary study of the efficacy of ondansetron in the treatment of ataxia, poor balance and incoordination from brain injury.
    Mandelcorn J; Cullen NK; Bayley MT
    Brain Inj; 2004 Oct; 18(10):1025-39. PubMed ID: 15370901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Postoperative delirium treated with physostigmine].
    Klauber V
    Ugeskr Laeger; 1979 Jan; 141(5):292-5. PubMed ID: 366845
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.